With support from LabCorp, partnership aims to bring trials to patients in south central Kentucky.
Graves Gilbert and Circuit Clinical broke the news that they will be collaborating to bring clinical trials to patients in South Central Kentucky. As part of the joint venture, the organizations intend to reduce the burden on patients who opt in for research participation. Localizing research participant care within Graves Gilbert's physician offices, Circuit Clinical supports the care provider team with embedded staff who have clinical trial experience and work side-by-side with the physicians in practice.
According to a company press release, the partnership was made possible through LabCorp. As the primary reference laboratory for Graves Gilbert, LabCorp will help identify clinical trials for which Graves Gilbert patients may be eligible, and the parties will work together to enroll patients into the trials quickly.
"We look forward to continuing to serve our diverse communities by offering patients access to clinical trials and cutting-edge treatments all from the comfort of our offices, with the physicians they know and trust," said Chris Thorn, CEO, Graves Gilbert.
Reference: Graves Gilbert, Circuit Clinical, and Labcorp Join Forces to Bring Clinical Trials to Patients across South Central Kentucky. PR Newswire. September 27, 2023. Accessed September 28, 2023. https://www.prnewswire.com/news-releases/graves-gilbert-circuit-clinical-and-labcorp-join-forces-to-bring-clinical-trials-to-patients-across-south-central-kentucky-301940562.html
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.